B-cell Lymphoma

CLINICAL_TRIALS trial_result · 2025-06-04

Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1]

Phase 1 study evaluating CD19/CD22 CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell maligna…

CLINICAL_TRIALS trial_result · 2025-06-03

Clinical Trial Update: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]

Phase 1 trial evaluating a triple-targeted CD19/CD20/CD22 cell therapy for relapsed/refractory B-cell lymphoma was terminated. The study sta…

CLINICAL_TRIALS trial_result · 2025-03-30

Clinical Trial Update: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies [Phase 1]

This is a Phase 1 clinical trial update on CD22-directed CAR T cells for children and young adults with B-cell malignancies, including B-cel…

CLINICAL_TRIALS trial_result · 2025-02-04

Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]

Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…

CLINICAL_TRIALS trial_result · 2025-01-22

Clinical Trial Update: Phase Ib Clinical Study of Keynatinib [Phase 1]

A Phase Ib study of Keynatinib for B-cell lymphoma is currently recruiting.

CLINICAL_TRIALS trial_result · 2025-01-14

Clinical Trial Update: Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma [Phase 2]

A Phase 2 clinical trial update indicates Sepantronium bromide is being studied for high-grade B-cell lymphomas, with the study currently ac…

CLINICAL_TRIALS trial_result · 2024-12-12

Clinical Trial Update: CAR-37 T Cells in Hematologic Malignancies [Phase 1]

Phase 1 trial update on CAR-37 T cells in hematologic malignancies shows the study has completed.

CLINICAL_TRIALS trial_result · 2024-12-11

Clinical Trial Update: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies [Phase 1]

A Phase 1 study of the bispecific antibody MCLA-145 in adults with advanced or metastatic malignancies has completed enrollment.

CLINICAL_TRIALS trial_result · 2024-12-06

Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]

Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…

CLINICAL_TRIALS trial_result · 2024-12-02

Clinical Trial Update: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma [Phase 1, Phase 2]

Phase 1/2 trial update on the combination of rituximab and varlilumab immunotherapy in patients with B-cell lymphoma, now completed.

CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]

Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…

CLINICAL_TRIALS trial_result · 2024-08-20

Clinical Trial Update: CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies [Phase 2]

This update announces the completion of a Phase 2 trial evaluating CD19-CAR-T2 cells for CD19-positive B-cell malignancies, including B-cell…

CLINICAL_TRIALS trial_result · 2024-07-22

Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]

Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…

CLINICAL_TRIALS trial_result · 2024-07-16

Clinical Trial Update: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) [Phase 2]

Phase 2 clinical trial update on LOXO-305 (pirtobrutinib) in Chinese participants with B-cell malignancies, with results posted on July 16, …

CLINICAL_TRIALS trial_result · 2024-06-11

Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]

Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.

CLINICAL_TRIALS trial_result · 2024-05-28

Clinical Trial Update: A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy [Phase 1]

Phase 1 clinical trial update for C-CAR066 in relapsed/refractory B-cell lymphoma patients who previously received CD19 CAR-T therapy.

CLINICAL_TRIALS trial_result · 2024-05-24

Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]

A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.

CLINICAL_TRIALS trial_result · 2024-03-25

Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma [Phase 1]

Phase 1 study evaluating safety and efficacy of Glofitamab or Mosunetuzumab with gemcitabine plus oxaliplatin in relapsed/refractory B-cell …

CLINICAL_TRIALS trial_result · 2024-02-07

Clinical Trial Update: A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma [Phase 1, Phase 2]

A clinical trial update for MIL62 combined with Orelabrutinib in relapsed/refractory B-cell lymphoma (Phase 1/2).

CLINICAL_TRIALS trial_result · 2023-12-29

Clinical Trial Update: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma [Phase 1, Phase 2]

A phase 1/2 clinical trial evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory B-cell lymphoma.

CLINICAL_TRIALS trial_result · 2023-09-21

Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]

Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…

CLINICAL_TRIALS trial_result · 2023-08-04

Clinical Trial Update: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL [Phase 1, Phase 2]

Clinical trial update for tazemetostat as a single agent and in combination in B-cell lymphomas and solid tumors completed with results post…

CLINICAL_TRIALS trial_result · 2023-07-11

Clinical Trial Update: A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]

Phase 1/2 study evaluating a novel anti-CD19 CAR-T therapy in patients with relapsed/refractory B-cell malignancies (leukemia and lymphoma).

CLINICAL_TRIALS trial_result · 2023-04-18

Clinical Trial Update: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

Phase 1/2 trial updating CAR-T therapy targeting CD19 and CD22 for relapsed/refractory B-cell leukemia and lymphoma.

CLINICAL_TRIALS trial_result · 2023-04-18

Clinical Trial Update: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma [Phase 1, Phase 2]

Clinical trial update for a CD19 and CD22 targeted PRIME CAR-T cell therapy in relapsed/refractory B cell lymphoma (Phase 1/Phase 2).

Top drugs studied for this disease